Pyrroloquinoline quinone ameliorates l‐thyroxine‐induced hyperthyroidism and associated problems in rats. (22nd July 2014)

• Record Type: Journal Article
• Authors: Kumar, Narendra; Kar, Anand; Panda, Sunanda
• Is Part Of: Cell biochemistry and function. Volume 32:Number 6(2013:Aug.)
• Page Start: 538
• Page End: 546
• Publication Date: 2014-07-22
• Subjects: Cytochemistry -- Periodicals; Cell metabolism -- Periodicals; Biochemistry -- Periodicals; Cytology -- Periodicals; 572
• DOI: 10.1002/cbf.3048
• Languages: English
• ISSNs: 0263-6484

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Pyrroloquinoline quinone (PQQ) is believed to be a strong antioxidant. In this study, we have evaluated its hitherto unknown role in <sc>l</sc>‐thyroxin (L‐T<sub>4</sub>)‐induced hyperthyroidism considering laboratory rat as a model. Alterations in the serum concentration of thyroxin (T<sub>4</sub>) and triiodothyronine (T<sub>3</sub>); lipid peroxidation (LPO) of liver, kidney, heart, muscles and brain; in the endogenous antioxidants such as superoxide dismutase, catalase and glutathione and in serum total cholesterol, high‐density lipoprotien, triglycerides, serum glutamate pyruvate transaminase (SGPT), serum glutamate oxaloacetate transaminase (SGOT) and urea were evaluated. Administration of <sc>l</sc>‐T<sub>4</sub> (500‐µg kg<sup>−1</sup> body weight) enhanced not only the serum T<sub>3</sub> and T<sub>4</sub> levels but also the tissue LPO, serum SGOT, SGPT and urea with a parallel decrease in the levels of antioxidants and serum lipids. However, on simultaneous administration of PQQ (5 mg kg<sup>−1</sup> for 6 days), all these adverse effects were ameliorated, indicating the potential of PQQ in the amelioration of hyperthyroidism and associated problems. Possibly, the curative effects were mediated through inhibition of oxidative stress. We suggest that PQQ may be considered for therapeutic use for hyperthyroidism after dose standardization. Copyright © 2014 John Wiley & Sons, Ltd.</p> </abstract>